

November 2011

**ANNUAL DECLARATION OF INTERESTS  
GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE  
SCIENCE COMMITTEE  
1 January 2011 – 31 December 2011**

GOLD participants disclose relationships (personal benefits, shares, and non-personal interests) with profit-making organizations each year using the following definitions.

- 1. *Personal Benefits*** refers to fees for lectures, advisory committees or consultancy services either intermittent or regular, from which a GOLD member benefits personally. This includes ongoing attendance at advisory board meetings.
- 2. *Shares*** refers to any shares in the pharmaceutical industry, excluding unit trusts, pension plans or mutual funds, and it refers to shares held by a GOLD member or family members (spouse/dependent children <18 yrs). The company is to be listed, not the number of shares.
- 3. *Non-Personal Interests*** refers to fees or grants paid to a GOLD Committee member (or the Department/Institution on behalf of a GOLD member) and used for research, education, equipment, salaries, etc.

For each category, items are included in one of two categories: payment or service is valued in excess of \$10,000 (US) but less than \$10,000 and payment or service is valued in excess of \$10,000. The information disclosed by each member of the Science Committee for the year 2011 is presented in an effort to be as transparent as possible. For more complete background about this process, see “Annual Declaration of Interests: Global Initiative for Chronic Obstructive Lung Disease (GOLD)” on the website at: <<http://www.goldcopd.org>>.

**SUMMARY FOR YEAR 2011:**

**Alvar Agusti, Barcelona, Spain:** *Personal Benefits* <\$10,000: Almirall, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Medimmune, Merck Sharp & Dohme, Novartis, Nycomed, Pfizer, Procter&Gamble. *Shares:* none. *Non-Personal Interests* >\$10,000: Almirall, GlaxoSmithKline, Nycomed.

**Antonio Anzueto, San Antonio, Texas, US:** *Personal Benefits* <\$10,000: Dey, Forest Labs, Sepracor. *Personal Benefits* >\$10,000: AstraZeneca, Bayer-Shering Pharma, Boehringer-Ingelheim, GlaxoSmithKline, Pfizer. *Shares:* none. *Non-Personal Interests* >\$10,000: GlaxoSmithKline, Lilly, Pfizer.

**Peter Barnes, London, England:** *Personal Benefits* >\$10,000: AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis, Nycomed, Pfizer, RespiVert. *Shares:* none. *Non-Personal Interests* >\$10,000: Aquinox, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Nycomed, Pfizer.

**Leonardo M. Fabbri, Modena, Italy:** *Personal Benefits* <\$10,000: Elevati Pharma, Euromediform, Ferrero Group, Genetech Inc, GlaxoSmithKline, Mundipharma, Novartis, OM Pharma, Parexell, Pearl Therapeutics, Peer Voice, Sterna. *Personal Benefits* >\$10,000: Boehringer-

Ingelheim, Chiesi, Merck Sharp & Dohme, Nycomed. *Shares*: none. *Non-Personal Interests >\$10,000*: Almirall, AstraZeneca, Boehringer-Ingelheim, Chiesi Int., GlaxoSmithKline, Merck Sharp & Dohme, Medestea, Menarini, Novartis, Nycomed, Pfizer, ScheringPlough, Sigma-Tau.

**Paul Jones, London, UK:** *Personal Benefits <\$10,000*: AstraZeneca, Almirall, Bayer, Boehringer-Pfizer, Chiesi, Novartis, Roche, Spiration. *Personal Benefits >\$10,000*: GlaxoSmithKline. *Shares*: none. *Non-Personal Interests >\$10,000*: GlaxoSmithKline, Novartis.

**Fernando Martinez, Ann Arbor, Michigan:** *Personal Benefits <\$10,000*: Actelion, Almirall, Boehringer Ingelheim, Centocor, CMEIncite, France Foundation, Forest, Ikaria, Gilead, MedEd, Merck Sharp & Dohme, Novartis, Pearl, Pfizer, Prescott, Quark, Sanofi Aventis, UpToDate. *Personal Benefits >\$10,000*: AstraZeneca/MedImmune, Bayer, ePocrates, GlaxoSmithKline, Nycomed/Forest. *Shares*: none. *Non-Personal Interests*: none.

**Masaharu Nishimura, Sapporo, Japan:** *Personal Benefits <\$10,000*: Abbott Japan, AstraZeneca Japan, GlaxoSmithKline Japan, Nippon Boehringer Ingelheim, Novartis Japan, Pfizer Japan. *Shares*: none. *Non-Personal Interests <\$10,000*: AstraZeneca Japan, Kyowa Hakko Kirin, Nippon Kayaku, ONO Pharmaceutical, Sanofi-Aventis Japan, Teijin Pharma. *Non-Personal Interests >\$10,000*: Astellas Pharma, Eli Lilly Japan, MerckSharpDohme Japan, Nippon Boehringer Ingelheim, Pfizer Japan, Takeda Pharmaceutical.

**Roberto Rodriguez-Roisin, Barcelona Spain:** *Personal Benefits <\$10,000*: Boehringer-Ingelheim, Merck Sharp & Dohme, Nycomed, Pear Therapeutics, Procter & Gamble. *Personal Benefits >\$10,000*: Novartis. *Shares*: none. *Non-Personal Interests <\$10,000*: Esteve, SA. *Non-Personal Interests >\$10,000*: Almirall.

**Don Sin, Vancouver BC, Canada:** *Personal Benefits <\$10,000*: AstraZeneca, GlaxoSmithKline, Pfizer. *Shares*: none. *Non-Personal Interests <\$10,000*: Bayer, Nycomed, Talecris. *Non-Personal Interests >\$10,000*: AstraZeneca, GlaxoSmithKline, Pfizer.

**Robert A. Stockley, Birmingham, UK:** *Personal Benefits <\$10,000*: AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Nycomed, Talecris Biotherapeutics. *Shares*: none. *Non-Personal Interests >\$10,000*: Talecris Biotherapeutics.

**Jorgen Vestbo, Hvidore Denmark:** *Personal Benefits <\$10,000*: AstraZeneca, Boehringer-Ingelheim, Bioxydyn, Chiesi, Nycomed, Pfizer. *Personal Benefits >\$10,000*: GlaxoSmithKline. *Shares*: none. *Non-Personal Interests >\$10,000*: GlaxoSmithKline.

**Claus Vogelmeier, Marburg Germany:** *Personal Benefits <\$10,000*: AstraZeneca, Chiesi, GlaxoSmithKline, Janssen-Cilag, Mundipharma, Novartis, Nycomed, Pfizer, Talecris, *Personal Benefits >\$10,000*: Boehringer-Ingelheim *Shares*: none. *Non-Personal Interests >\$10,000*: Talecris.

***All members confirmed no relation to, or income from, the tobacco industry.***